BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17291253)

  • 1. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
    Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
    Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
    Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
    Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
    Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
    Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
    Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
    Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
    Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Leunen K; Berteloot P; Neven P; Amant F
    Int J Gynecol Cancer; 2009 Aug; 19(6):1147-51. PubMed ID: 19820384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
    Michener CM; Peterson G; Kulp B; Webster KD; Markman M
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
    Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Neven P; Amant F
    Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
    Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
    Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
    Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
    Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
    Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
    J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
    Hoskins PJ; Swenerton KD; Pike JA; Wong F; Lim P; Acquino-Parsons C; Lee N
    J Clin Oncol; 2001 Oct; 19(20):4048-53. PubMed ID: 11600606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
    Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
    Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.
    Sovak MA; Hensley ML; Dupont J; Ishill N; Alektiar KM; Abu-Rustum N; Barakat R; Chi DS; Sabbatini P; Spriggs DR; Aghajanian C
    Gynecol Oncol; 2006 Nov; 103(2):451-7. PubMed ID: 16677690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
    Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
    Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.